Abstract
We report a patient with B-cell prolymphocytic leukemia (PLL) who was treated successfully with the monoclonal anti-CD20 antibody (rituximab). The patient had recurrent infections due to relative neutropenia, secondary to bone marrow infiltration. After treatment with monoclonal anti-CD20 antibodies (rituximab) 375 mg/m2 weekly for 4 weeks, complete remission was obtained. It was documented by normalization of peripheral blood counts, disappearance of organomegaly, and by molecular cytogenetics-fluorescent in situ hybridization (FISH) on bone marrow cells. She remains in complete remission 8 months following the discontinuation of treatment. This is the second reported case of successful treatment of B-cell PLL with rituximab.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Anderson KC, Bates MP, Slougenhoupt BL, et al. (1984) Expression of human B-cell associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 63:1424–1433
Tedder TF, Engel P (1994) CD 20: a regulator of cell-cycle progression of B-lymphocytes. Immunol Today 15:450–454
Reff ME, Carner K, Chambers KS, et al. (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD 20. Blood 83:435–445
Maloney D, Grillo-Lopez AJ, White CA, et al. (1997) IDEC C2B8 (Rituxan AB) anti-CD 20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphomas. Blood 90:2188–2195
McLaughlin P, Grillo-Lopez AJ, Link BK, et al. (1998) Rituximab chimeric anti-CD 20 monoclonal antibody therapy for relapsed indolent lymphoma: half of the patients respond to a four-dose treatment program. J Clin Oncol 16:2825–2833
Czuczman MS, Grillo-Lopez AJ, White CA, et al. (1999) Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD 20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17:268–276
Vartholomatos G, Tsiara S, Christou L, et al. (1999) Rituximab (anti-CD20 monoclonal antibody) administration in a young patient with resistant B-prolymphocytic leukemia. Acta Haematol 102:94–98
Perz J, Topaly J, Fruehauf S, et al. (2002) Level of CD 20-expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia. Leuk Lymphoma 43:149–151
Byrd JC, Waselenko JK, Maniatis TJ, et al. (1999) Rituximab therapy in hematologic malignancies patients with circulating blood tumor cells: association with increased infusion related side effects and rapid tumor clearance. J Clin Oncol 17:791–795
J.Boye, T.Elter, A.Engert (2003) An overview of the current clinical use of the anti-CD 20 monoclonal antibody Rituximab. Ann Oncol 14:520–535
Acknowledgements
We thank Miss Maya Charafeddine for her editorial assistance.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mourad, Y.A., Taher, A., Chehal, A. et al. Successful treatment of B-cell prolymphocytic leukemia with monoclonal anti-CD20 antibody. Ann Hematol 83, 319–321 (2004). https://doi.org/10.1007/s00277-003-0805-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-003-0805-z